Skip to main content

Status Conference Schedule Out For Valsartan Recall Lawsuits

Status Conference Schedule Out For Valsartan Recall Lawsuits

Status Conference Schedule Out For Valsartan Recall Lawsuits

Introduction

According to a case management order dated April 2, valsartan lawsuits can proceed in the U.S. District Court, District of New Jersey, where federal claims, arising because of the generic drug recall, are currently undergoing pretrial proceedings.

The order stated the litigation would assemble a two-part status conference on the fourth Wednesday of every month. The first session of each conference, beginning at 10 a.m., will look into the discovery matters linked to valsartan lawsuits. The second part beginning at 1.30 p.m. will address various case management and scheduling issues. A telephonic conference with the lead counsel will be arranged by the Plaintiffs' counsel two weeks before each status conference at 4.00 p.m. The litigation will call for its next status conference on April 24, when the court will address various issues, including the appointment of attorneys to plaintiffs’ leadership committees. By April 10, Plaintiffs’ Leadership Counsel must inform all attorneys with valsartan lawsuits regarding their desire to join a committee earliest by April 10. The attorneys are supposed to respond to the inquiry by April 18, after which the lead counsel will submit a list of nominations by close of business on April 22. Valsartan recall was initiated last year following numerous reports that the blood pressure drug contains cancer-causing nitrosamines in it. Since then, dozens of generic drug makers recalled the medication.

As of March 15, 43 valsartan lawsuits were pending in the federal multidistrict litigation, which includes individual as well as class action complaints alleging that the drugs cause cancer.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!